This is a preview of subscription content, log in via an institution to check access.
Notes
2019 British pounds
References
1. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND55, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/107862
2. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Forms of Multiple Sclerosis. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND47, 16 Nov 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2020-3282/107814
Rights and permissions
About this article
Cite this article
Socioeconomic benefits of ocrelizumab for multiple sclerosis. PharmacoEcon Outcomes News 868, 32 (2020). https://doi.org/10.1007/s40274-020-7364-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7364-6